The Readout Loud 353: Trump's drug-pricing plan and a potential Theranos 2.0
May 15, 2025
Daniel Payne, STAT's D.C. correspondent specializing in health policy and pharma, dives into the complexities of President Trump's aggressive drug pricing policy aimed at making U.S. prices competitive with other nations. He also discusses the mixed outlook for biotech markets and the potential launch of a new blood-testing company founded by Billy Evans, which draws parallels to the notorious Theranos. The episode paints a vivid picture of skepticism in the industry as market fluctuations and past scandals loom large.
AI Snips
Chapters
Transcript
Episode notes
Biotech Stocks Show Signs of Recovery
- Biotech stocks showed a slight rebound in recent weeks despite persistent frustrations.
- Small to mid-cap development-stage biotech firms have performed better, hinting at possible recovery.
Biotech Companies Facing Reality
- Biotech companies facing cash shortages are reevaluating their futures, including liquidation or returning cash to shareholders.
- This trend indicates a maturing sector with more realistic management decisions.
Theranos 2.0 Concerns
- Billy Evans, Elizabeth Holmes' husband, is starting a new blood-testing company amid skepticism.
- The prototype allegedly resembles Theranos technology, raising investor concerns about a "Theranos 2.0."